Go Deep
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,402 | 18.3 | 2.42 | 0.09 | 72,092.02 |
| Oct 2026 | 20,260 | 18.9 | 2.48 | 0.09 | 73,031.83 |
| Oct 2026 | 20,375 | 18.6 | 2.44 | 0.09 | 71,722.40 |
| Oct 2026 | 20,186 | 19.2 | 2.53 | 0.09 | 73,903.33 |
| Oct 2026 | 20,053 | 19.1 | 2.58 | 0.09 | 75,621.27 |
| Oct 2026 | 20,094 | 19.6 | 2.57 | 0.09 | 74,894.90 |
| Oct 2026 | 20,159 | 19.3 | 2.54 | 0.09 | 74,150.21 |
| Oct 2026 | 19,969 | 20.0 | 2.62 | 0.09 | 76,562.34 |
| Oct 2026 | 19,983 | 19.9 | 2.62 | 0.09 | 76,202.02 |
| Oct 2026 | 19,882 | 20.3 | 2.66 | 0.09 | 77,314.58 |
| Oct 2026 | 19,987 | 19.9 | 2.61 | 0.09 | 76,301.55 |
Regeneron Pharmaceuticals, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 4,290,700,000.0 | 3,605,400,000.0 | 3,884,300,000.0 | 3,754,300,000.0 |
| Net Profit | 1,296,900,000.0 | 727,200,000.0 | 844,600,000.0 | 1,460,000,000.0 |
| EPS | 12.6 | 7.0 | 8.2 | 14.1 |
Regeneron Pharmaceuticals, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 14,342,900,000.0 | 14,202,000,000.0 | 13,117,200,000.0 | 12,172,900,000.0 | — |
| Net Profit | 4,504,900,000.0 | 4,412,600,000.0 | 3,953,600,000.0 | 4,338,400,000.0 | — |
| EPS | 43.1 | 40.9 | 37.0 | 40.5 | — |
Regeneron Pharmaceuticals, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 40,558,700,000.0 | 37,759,400,000.0 | 33,080,200,000.0 | 29,214,500,000.0 | — |
| Total Liabilities | 9,301,800,000.0 | 8,405,800,000.0 | 7,107,100,000.0 | 6,550,500,000.0 | — |
| Total Equity | 31,256,900,000.0 | 29,353,600,000.0 | 25,973,100,000.0 | 22,664,000,000.0 | — |
Owes vs Owns
Regeneron Pharmaceuticals, Inc. owed $0.24 for every $1 it owned in Jun 2026, up from $0.22 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.24× | 0.23× | 0.22× | 0.21× | 0.22× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Regeneron Pharmaceuticals, Inc. Assets & Liabilities Breakdown (₹ Cr)
What it owns — Dec 2025
Cash & short-term investments 21.2%Receivables 14.2%Inventory 7.9%Fixed assets (tangible) 12.6%Intangible assets 3.1%Long-term investments 25.3%Other assets 15.7%
How it's funded — Dec 2025
Long-term debt 4.9%Payables 2.3%Other liabilities 15.7%Shareholders' equity 77.1%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 860.5 | 901.2 | 1,084.5 | 774.2 |
| Receivables | 574.1 | 621.2 | 566.7 | 532.9 |
| Inventory | 320.1 | 308.7 | 258.1 | 240.2 |
| Fixed assets (tangible) | 512.0 | 460.0 | 414.6 | 376.3 |
| Intangible assets | 125.7 | 114.9 | 103.9 | 91.5 |
| Long-term investments | 1,026.1 | 890.0 | 539.6 | 659.2 |
| Other assets | 637.3 | 479.9 | 340.6 | 247.1 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term debt | 198.6 | 198.4 | 198.3 | 198.1 |
| Payables | 93.9 | 79.0 | 60.7 | 58.9 |
| Other liabilities | 637.7 | 563.2 | 451.8 | 398.0 |
| Shareholders' equity | 3,125.7 | 2,935.4 | 2,597.3 | 2,266.4 |
| Net tangible assets | 2,999.9 | 2,820.5 | 2,493.4 | 2,174.8 |
Regeneron Pharmaceuticals, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 4,978,900,000.0 | 4,420,500,000.0 | 4,594,000,000.0 | 5,014,900,000.0 | — |
| Investing Activities | -629,100,000.0 | -2,468,100,000.0 | -3,185,100,000.0 | -3,784,600,000.0 | — |
| Financing Activities | -3,715,400,000.0 | -2,200,500,000.0 | -1,790,100,000.0 | -1,009,000,000.0 | — |